Pharmacological profiles of generalized absence seizures in lethargic, stargazer and gamma-hydroxybutyrate-treated model mice
about
New vistas on astroglia in convulsive and non-convulsive epilepsy highlight novel astrocytic targets for treatmentExcitatory but not inhibitory synaptic transmission is reduced in lethargic (Cacnb4(lh)) and tottering (Cacna1atg) mouse thalamiEnhanced tonic GABAA inhibition in typical absence epilepsy.Recent advances in the genetics of epilepsy: insights from human and animal studies.Enhanced NMDA receptor-dependent thalamic excitation and network oscillations in stargazer mice.Animal models of absence epilepsies: what do they model and do sex and sex hormones matter?GABAB receptor antagonist CGP46381 inhibits form-deprivation myopia development in guinea pigs.Ethosuximide reduces electrographical and behavioral correlates of alcohol withdrawal seizure in DBA/2J mice.Oral administration of fructose-1,6-diphosphate has anticonvulsant activity.T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.Novel astrocyte targets: new avenues for the therapeutic treatment of epilepsyA critical evaluation of the gamma-hydroxybutyrate (GHB) model of absence seizures.The Role of Calcium Channels in Epilepsy.γ-Hydroxybutyric acid-induced electrographic seizures.NMDA Receptor Expression in the Thalamus of the Stargazer Model of Absence Epilepsy.Paradoxical proepileptic response to NMDA receptor blockade linked to cortical interneuron defect in stargazer micePharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome.Synaptic Changes in AMPA Receptor Subunit Expression in Cortical Parvalbumin Interneurons in the Stargazer Model of Absence Epilepsy.
P2860
Q27011409-2506E96A-05E4-48A4-BC58-782E78E371E5Q28590366-03622A04-CEBE-47FA-BBBC-72F16375C782Q30493216-CA6A60F6-CFB0-4C25-81DE-AA8CCB8F1725Q33755692-C7DA9B6D-F5BC-4C97-BC58-A086CACF47EBQ34372204-B7FF4154-A412-421C-A4C5-894D3ACCD60BQ34615606-1955F43E-7AEA-47C7-BE5E-7C49BD3E04C6Q35012434-C485FE36-B7F2-423F-96AC-2E267765230CQ35231077-98CF2313-315E-49D7-A0A1-F74E30D8DB90Q37077754-E54D24BB-C4D7-48B6-8BBC-CB3D54E063C1Q37209052-AD87AF36-2A8E-47CA-AC7C-864B9C050AD0Q38194448-16B01EB6-405D-4B62-BE31-D95BDE2D61FEQ38268879-489D1BBD-2E95-4307-B0AF-0C9492C0B4EEQ38686593-2E4ACA33-71EF-4E6B-B01A-3C01E49ED066Q41031578-B3B31FE1-B874-4269-910B-9EF6E8881A1DQ41963338-DC489252-FDCD-429F-AF3C-4BD234018409Q42631183-D4A41848-978E-455E-85AF-3DDA74A1A690Q46879489-D0C60C89-76E8-48C4-9EB7-094800F01AEAQ47194894-6B3C9D21-F538-474A-9E96-9677BFC88377
P2860
Pharmacological profiles of generalized absence seizures in lethargic, stargazer and gamma-hydroxybutyrate-treated model mice
description
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1997
@ast
scientific journal article
@en
vedecký článok (publikovaný 1997/09/01)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/09/01)
@nl
наукова стаття, опублікована у вересні 1997
@uk
مقالة علمية (نشرت في سبتمبر 1997)
@ar
name
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@ast
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@en
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@nl
type
label
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@ast
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@en
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@nl
prefLabel
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@ast
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@en
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@nl
P2093
P921
P1476
Pharmacological profiles of ge ...... oxybutyrate-treated model mice
@en
P2093
P356
10.1016/S0168-0102(97)00066-7
P577
1997-09-01T00:00:00Z